Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14783355 | 0.81 | CFTR (0.58) | KMT2AALDH1A1PDCD1CD274MEN1 | |
| SCHEMBL28088014 | 0.75 | CES1 (0.42) | ALDH1A1PDCD1CD274KDM4ETDP1 | |
| SCHEMBL2372225 | 0.74 | MLYCD (0.49) | KMT2AALDH1A1MEN1SMN1; SMN2HDAC6 | |
| SCHEMBL14784231 | 0.72 | PDK1 (0.36) | KMT2AMEN1PLAULMNAMAPT | |
| SCHEMBL2372260 | 0.71 | CFTR (0.38) | ALDH1A1KDM4EHTTTDP1PLAU | |
| SCHEMBL2371638 | 0.70 | HDAC2 (0.50) | ALDH1A1SMN1; SMN2HDAC8HDAC6NPC1 | |
| SCHEMBL4722661 | 0.68 | KMT2A (0.79) | KMT2AALDH1A1PDCD1CD274MEN1 | |
| SCHEMBL14816556 | 0.68 | MTOR (0.42) | KMT2AMEN1SMN1; SMN2LMNANPC1 | |
| SCHEMBL7107935 | 0.67 | ALDH1A1 (0.77) | KMT2AALDH1A1MEN1POLBKDM4E | |
| SCHEMBL2373061 | 0.66 | NAMPT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2755967-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | KMT2A 4300/4885ALDH1A1 1691/4885PDCD1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.